13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001055951
Total reported value
$5.4B
$5.4B
105 檔
23.6%
During the Q4 2025 filing period, Orbimed Advisors LLC (CIK: 0001055951) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $5.4B across 105 reported positions.
Orbimed Advisors LLC executed strategic sector rebalancing during Q4 2025, establishing 23 new positions while fully exiting 22 holdings and trimming 36 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 8.14% | +1.73% | — | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 6.84% | +1.30% | — | |
| 3 | BSX | Boston Scientific CORP | Stock-Healthcare | 4.87% | -1.88% | -7.99% | |
| 4 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 3.59% | -0.61% | +18.34% | |
| 5 | UPB | Upstream Bio Inc | Stock-Other | 3.27% | -0.32% | — | |
| 6 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.15% | -0.80% | -8.29% | |
| 7 | SION | Sionna Therapeutics Inc | Stock-Other | 3.10% | -0.80% | -3.87% | |
| 8 | MBX | Mbx Biosciences Inc | Stock-Other | 2.62% | +1.30% | -1.69% | |
| 9 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.59% | -0.44% | -15.26% | |
| 10 | ELVN | Enliven Therapeutics Inc | Stock-Other | 2.59% | +0.02% | — | |
| 11 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.43% | -0.71% | -4.24% | |
| 12 | SYK | Stryker CORP | Stock-Healthcare | 2.41% | -0.30% | -9.52% | |
| 13 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 2.04% | -0.12% | — | |
| 14 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.84% | — | -71.53% | |
| 15 | IRON | Disc Medicine Inc | Stock-Other | 1.79% | -0.91% | -24.56% | |
| 16 | CAI | Caris Life Sciences Inc | Stock-Other | 1.78% | -0.10% | +2.67% | |
| 17 | NTRA | Natera Inc | Stock-Healthcare | 1.77% | +0.26% | -14.79% | |
| 18 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.73% | -1.03% | — | |
| 19 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.71% | +0.75% | +1.98% | |
| 20 | DHR | Danaher CORP | Stock-Healthcare | 1.45% | -1.03% | EXIT | |
| 21 | CGON | Cg Oncology Inc | Stock-Other | 1.33% | -0.03% | -12.18% | |
| 22 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.29% | — | -5.58% | |
| 23 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.29% | +0.53% | — | |
| 24 | CI | THE Cigna Group | Stock-Healthcare | 1.19% | — | +25.92% | |
| 25 | RAPT | Rapt Therapeutics Inc | Stock-Other | 1.18% | — | +51.19% | |
| 26 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 1.17% | -0.16% | — | |
| 27 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.08% | — | -8.44% | |
| 28 | ABVX | Abivax Sa-adr | Stock-Other | 1.05% | +0.79% | -3.18% | |
| 29 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 1.00% | — | -19.30% | |
| 30 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.98% | -0.04% | -16.68% | |
| 31 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.98% | -0.20% | -52.40% | |
| 32 | EYPT | Eyepoint Inc | Stock-Other | 0.95% | — | +37.43% | |
| 33 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.94% | — | -62.20% | |
| 34 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.94% | — | -11.14% | |
| 35 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.91% | +0.26% | -4.84% | |
| 36 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 0.88% | -0.16% | — | |
| 37 | PFE | Pfizer Inc | Stock-Healthcare | 0.87% | -1.12% | EXIT | |
| 38 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.84% | -0.10% | -3.56% | |
| 39 | NPCE | Neuropace Inc | Stock-Other | 0.78% | -0.11% | -7.95% | |
| 40 | ASND | Ascendis Pharma A/S | Stock-Other | 0.77% | -0.85% | EXIT | |
| 41 | EXK | Exact Sciences CORP | Stock-Materials | 0.75% | — | -64.64% | |
| 42 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.75% | -0.08% | -33.28% | |
| 43 | ELV | Elevance Health Inc | Stock-Healthcare | 0.73% | +0.21% | — | |
| 44 | FBRX | Forte Biosciences Inc | Stock-Other | 0.69% | -0.02% | — | |
| 45 | PRLD | Prelude Therapeutics Inc | Stock-Other | 0.67% | +0.60% | — | |
| 46 | HELP | Cybin Inc | Stock-Other | 0.66% | +0.02% | — | |
| 47 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.63% | -0.29% | — | |
| 48 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.62% | +0.21% | +16.60% | |
| 49 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.59% | +0.30% | — | |
| 50 | JANX | Janux Therapeutics Inc | Stock-Other | 0.57% | -0.13% | +10.66% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EWTX | Edgewise Therapeutics Inc | +1.9% | — | Unchanged |
| 2 | LLY | Eli Lilly & Co | +1.2% | — | Unchanged |
| 3 | GPCR | Structure Therapeutics Inc | +0.9% | +1.98% | Add |
| 4 | MBX | Mbx Biosciences Inc | +0.9% | -1.69% | Trim |
| 5 | UPB | Upstream Bio Inc | +0.6% | — | Unchanged |
| 6 | PFE | Pfizer Inc | +0.5% | +230.58% | Add |
| 7 | RAPT | Rapt Therapeutics Inc | +0.5% | +51.19% | Add |
| 8 | 430 | Terns Pharmaceuticals Inc | +0.5% | -71.53% | Trim |
| 9 | SION | Sionna Therapeutics Inc | +0.4% | -3.87% | Trim |
| 10 | CMPX | Compass Therapeutics Inc | +0.4% | — | Unchanged |
| 11 | EW | Edwards Lifesciences CORP | +0.4% | +18.34% | Add |
| 12 | EYPT | Eyepoint Inc | +0.3% | +37.43% | Add |
| 13 | PRLD | Prelude Therapeutics Inc | +0.3% | — | Unchanged |
| 14 | ABVX | Abivax Sa-adr | +0.3% | -3.18% | Trim |
| 15 | FBRX | Forte Biosciences Inc | +0.3% | — | Unchanged |
| 16 | BRD1EUR | Mind Medicine Mindmed Inc | +0.2% | +233.50% | Add |
| 17 | DYN | Dyne Therapeutics Inc | +0.2% | -4.84% | Trim |
| 18 | DHR | Danaher CORP | +0.2% | +13.95% | Add |
| 19 | KRYS | Krystal Biotech Inc | +0.2% | +16.60% | Add |
| 20 | NPCE | Neuropace Inc | +0.1% | -7.95% | Trim |
| 21 | STTK | Shattuck Labs Inc | +0.1% | — | Unchanged |
| 22 | ✓ | Ikena Oncology Inc | +0.1% | — | Unchanged |
| 23 | BCRX | Biocryst Pharmaceuticals Inc | +0.1% | +93.21% | Add |
| 24 | TRVI | Trevi Therapeutics Inc | +0.1% | -3.56% | Trim |
| 25 | URGN | UroGen Pharma Ltd. | +0.1% | +27.07% | Add |
| 26 | BIOA | Bioage Labs Inc | +0.1% | — | Unchanged |
| 27 | NTRA | Natera Inc | +0.1% | -14.79% | Trim |
| 28 | BTSG | Brightspring Health Services | +0.1% | +18.05% | Add |
| 29 | CELC | Celcuity Inc | +0.1% | +1.96% | Add |
| 30 | JBIO | Jade Biosciences Inc | +0.1% | — | Unchanged |
| 31 | CI | THE Cigna Group | +0.1% | +25.92% | Add |
| 32 | QTTB | Q32 Bio Inc | +0.1% | — | Unchanged |
| 33 | AVTX | Avalo Therapeutics Inc | 0% | -12.01% | Trim |
| 34 | ALMS | Alumis Inc | 0% | -42.76% | Trim |
| 35 | RPTX | Repare Therapeutics Inc | 0% | — | Unchanged |
| 36 | INSM | Insmed Inc | 0% | +88.72% | Add |
| 37 | ANRO | Alto Neuroscience Inc | 0% | -50.00% | Trim |
| 38 | ISRG | Intuitive Surgical Inc | 0% | -8.29% | Trim |
| 39 | TMO | Thermo Fisher Scientific Inc | 0% | — | Unchanged |
| 40 | WHWK | Whitehawk Therapeutics Inc | 0% | — | Unchanged |
| 41 | SPRY | Ars Pharmaceuticals Inc | 0% | — | Unchanged |
| 42 | RYTM | Rhythm Pharmaceuticals Inc | 0% | +11.46% | Add |
| 43 | XENE | Xenon Pharmaceuticals Inc | 0% | +6.58% | Add |
| 44 | ROIV | Roivant Sciences Ltd. | — | -19.30% | Trim |
| 45 | NSPR | Inspiremd Inc | 0% | +46.87% | Add |
| 46 | TARS | Tarsus Pharmaceuticals Inc | 0% | -21.98% | Trim |
| 47 | IMA | Imagenebio Inc | 0% | — | Unchanged |
| 48 | TRAW | Traws Pharma Inc | 0% | — | Unchanged |
| 49 | VIR | Vir Biotechnology Inc | 0% | — | Unchanged |
| 50 | KROS | Keros Therapeutics Inc | -0.1% | -21.06% | Trim |
According to official SEC Form 13F filings, Orbimed Advisors LLC reported a total U.S. public equity portfolio value of $5.4B across 105 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including EWTX, LLY, BSX) accounted for 23.6% of total reported equity market value during Q4 2025.
Top New Position Initiated
BMY
市值: $41.8M
Top Position Liquidated / Trimmed
SIBN
前期市值: $38.0M
During Q4 2025, Orbimed Advisors LLC's top holdings by market value included EWTX (8.1%)、LLY (6.8%)、BSX (4.9%). The largest single position, EWTX, represented 8.1% of total portfolio value.
In Q4 2025, Orbimed Advisors LLC made 102 total portfolio adjustments, initiating 23 new buys, adding to 21 positions, trimming 36 holdings, and fully liquidating 22 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.